Cinacalcet

From Wikipedia, the free encyclopedia


Cinacalcet
Systematic (IUPAC) name
N-[(1R)-1-(1-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-1-amine
Identifiers
CAS number	226256-56-0
ATC code	H05BX01
PubChem	156419
DrugBank	APRD00872
Chemical data
Formula	C₂₂H₂₂F₃N
Mol. mass	357.412 g/mol
Pharmacokinetic data
Bioavailability	20 to 25% Increases if taken with food
Protein binding	93 to 97%
Metabolism	Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Half life	30 to 40 hours
Excretion	Renal (80%) and fecal (15%)
Therapeutic considerations
Licence data	EU, US
Pregnancy cat.	B3(AU) C(US)
Legal status	℞ Prescription only
Routes	Oral

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.^[1]

[edit] Clinical uses

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.

[edit] References

^ Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 16 (3): 253–8. doi:10.1053/j.jrn.2006.04.010. PMID 16825031.